Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04724473 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
A Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1,030
- Enrollment target
NCT04724473 is a Early Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,030 participants.
The verdict
NCT04724473, a Early Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1,030 participants
- Enrollment target
Study Summary
The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.
Interventions
- DRUG Tretinoin Cream 0.025%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2020-11-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04724473
The ClinicalTrials.gov registry entry for NCT04724473 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1,030 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tretinoin Cream 0.025% is the first listed.
NCT04724473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04724473 about?
NCT04724473 is a clinical study titled "A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris". The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.
What is the current status of trial NCT04724473?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1,030 participants. The study started on 2019-12-10. Estimated completion is 2020-11-21.
What interventions are being tested in trial NCT04724473?
The interventions under investigation include: Tretinoin Cream 0.025% (DRUG).
Who is sponsoring clinical trial NCT04724473?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.